Breast Cancer Prevention: What the NY Times Got Wrong

04/16/2013 In today’s New York Times (Tuesday April 16, 2013) there’s an article by Denise Grady which reports recommendations of the United States Preventive Services Task Force (USPSTF) who published a draft form of their recommendations for public comment concerning the drugs raloxifene (Evista) and tamoxifen (Nolvadex). As many of you are aware, I have published extensively on these drugs and participated in studies for both. Tamoxifen has been used for several decades, initially for wo...


Improving Sexual Comfort in Menopausal Patients

03/05/2013 This past week there has been a lot of news emanating from the FDA that concerns menopausal and perimenopausal women.  I would like to share some of this with you. A week ago the FDA, without using an Advisory Panel of outside experts, approved Ophena (generic name Ospemifene) for “treatment of moderate to severe dyspareunia (medical term for painful intercourse) a symptom of vulvar and vaginal atrophy due to menopause (the vaginal changes seen with no more estrogen production)...